Newsletter - March 2, 2017
FDA Under Attack: Should Industry Help?
In the recent days, FDA has come under constant attack for being “slow and burdensome” by none other than its own boss. The anecdotes have the risk of becoming mainstream when at the first address to the joint session of the Congress; the President uses a false case to demonstrate how the FDA process is delaying life-saving drugs from getting to the patients. Read More
India is the Main Non-US Producer of Prescription Drugs
This week the Office of Generic Drugs (OGD) released its annual report touting another year of record approvals of generic drugs. Almost 800 new generic drugs were approved last year by the OGD and just about half of them come from manufacturers based in India. Indian generic manufacturer had more approvals than even those located in the US. Read More
FDA Under Attack: Should Industry Help?
In the recent days, FDA has come under constant attack for being “slow and burdensome” by none other than its own boss. The anecdotes have the risk of becoming mainstream when at the first address to the joint session of the Congress; the President uses a false case to demonstrate how the FDA process is delaying life-saving drugs from getting to the patients. Read More
India is the Main Non-US Producer of Prescription Drugs
This week the Office of Generic Drugs (OGD) released its annual report touting another year of record approvals of generic drugs. Almost 800 new generic drugs were approved last year by the OGD and just about half of them come from manufacturers based in India. Indian generic manufacturer had more approvals than even those located in the US. Read More
